Filing Overview
Xeris Biopharma Holdings, Inc. filed a Form 8-K dated March 29, 2023, reporting an event occurring March 27, 2023. The filing concerns a board appointment and related director compensation; it does not report operating or financial results.
Business Context and Reporting Period
Xeris Biopharma Holdings is a Delaware corporation headquartered in Chicago, Illinois, with common stock traded on the Nasdaq Global Select Market under the symbol XERS. The company identified itself as an emerging growth company.
Key Financial and Capital Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating-performance metrics.
Material Changes and Corporate Governance
- The Board expanded from eight to nine members.
- Ricki Fairley was appointed as a Class III director effective March 27, 2023. Her term expires at the 2024 annual meeting of shareholders, unless a successor is elected and qualified earlier.
- Ms. Fairley was not appointed to a Board committee at the time of the filing.
- Ms. Fairley has more than 35 years of marketing experience, including prior brand-management and agency-leadership roles, and is co-founder and CEO of TOUCH, The Black Breast Cancer Alliance.
Compensation, Arrangements, and Other Matters
- Ms. Fairley received 85,000 restricted stock units. The awards vest in equal annual installments over three years beginning on the first anniversary of the grant date, subject to continued Board service. Each vested unit represents one share of common stock.
- Her director compensation follows the company’s existing non-employee director compensation policy, filed as Exhibit 10.1.
- The company entered into its standard director indemnification agreement with Ms. Fairley.
- The filing states that there were no appointment-related arrangements or understandings, no family relationships with directors or executive officers, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
Outlook, Risks, and Unusual Items
The filing contains no management outlook, financial guidance, contingencies, or operational risk update. The principal unusual item is the issuance of 85,000 restricted stock units in connection with the new director appointment.
Investor Verification Points
- Verify the vesting schedule and accounting treatment of the 85,000 restricted stock units.
- Review Exhibit 10.1 for the full non-employee director compensation policy.
- Confirm the Board’s nine-member composition and Ms. Fairley’s Class III term through the 2024 annual meeting.
- Refer to the company’s latest Form 10-K and subsequent filings for financial results, liquidity, debt, and business outlook, which are not included in this Form 8-K.